Clinical Research Directory

Inclusion Criteria: * Ability to understand and the willingness to sign informed consent prior to any study- related procedures. * Patients diagnosed with lymphoma. * Will receive first line R-CHOP or POLA-R-CHP chemotherapy regimens, patients do not need to be within a certain timeframe from diagnosis. * Aged ≥18 years; due to the rarity of the disease in those \<18 years, this age bracket will not be included. * Engaging in ≤60-minutes of structured moderate or vigorous intensity exercise. * Have physician clearance to participate in exercise. * Speak English. * Willing to travel to Dana-Farber Cancer Institute for necessary data collection and exercise sessions. * Access to a phone that can receive text messages. Exclusion Criteria: * Unstable comorbidities that prevent participation in moderate-to-vigorous intensity exercise. Patients with unstable comorbidities likely require supervised exercise for safety, and part of this study involves unsupervised exercise; therefore, for safety reasons, these persons are excluded. * Participate in more than 60 minutes of structured moderate-to-vigorous exercise per week over the last month. Excess additional exercise is a confounding factor in assessing the effect of the current interrupted sedentary time intervention. * Patients receiving treatment for other active malignancies (except basal cell carcinoma). This study is exclusively targeting lymphoma chemotherapy-related effects. * Subjects who in the opinion of the investigators may not be able to comply with the safety monitoring requirements of the study. * Unable to travel to DFCI Longwood campus for necessary data collection and chemotherapy infusions.